SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable.

Haeusler, IL; Daniel, O; Isitt, C; Watts, R; Cantrell, L; Feng, S; Cochet, M; Salloum, M; Ikram, S; Hayter, E; et al. Haeusler, IL; Daniel, O; Isitt, C; Watts, R; Cantrell, L; Feng, S; Cochet, M; Salloum, M; Ikram, S; Hayter, E; Lim, S; Hall, T; Athaide, S; Cosgrove, CA; Tregoning, JS; Le Doare, K (2022) Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable. Clin Exp Immunol, 209 (2). pp. 188-200. ISSN 1365-2249 https://doi.org/10.1093/cei/uxac066
SGUL Authors: Daniel, Olwenn Elea Le Doare, Kirsty Cosgrove, Catherine

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview
[img] Microsoft Word (.docx) (Supplementary data) Published Version
Available under License Creative Commons Attribution.

Download (91kB)
[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution.

Download (908kB)

Abstract

Group B Streptococcus (GBS) is a leading cause of adverse pregnancy outcomes due to invasive infection. This study investigated longitudinal variation in GBS rectovaginal colonization, serum and vaginal GBS capsular polysaccharide (CPS)-specific antibody levels. Non-pregnant women were recruited in the UK and were sampled every 2 weeks over a 12-week period. GBS isolates were taken from recto-vaginal swabs and serotyped by polymerase chain reaction. Serum and vaginal immunoglobulin G (IgG) and nasal immunoglobulin A (IgA) specific to CPS were measured by Luminex, and total IgG/A by ELISA. Seventy women were enrolled, of median age 26. Out of the 66 participants who completed at least three visits: 14/47 (29.8%) women that were GBS negative at screening became positive in follow-up visits and 16/19 (84.2%) women who were GBS positive at screening became negative. There was 50% probability of becoming negative 36 days after the first positive swab. The rate of detectable GBS carriage fluctuated over time, although serum, vaginal, and nasal CPS-specific antibody levels remained constant. Levels of CPS-specific antibodies were higher in the serum of individuals colonized with GBS than in non-colonized, but similar in the vaginal and nasal mucosa. We found correlations between antibody levels in serum and the vaginal and nasal mucosa. Our study demonstrates the feasibility of elution methods to retrieve vaginal and nasal antibodies, and the optimization of immunoassays to measure GBS-CPS-specific antibodies. The difference between the dynamics of colonization and antibody response is interesting and further investigation is required for vaccine development.

Item Type: Article
Additional Information: © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: GBS vaccine, capsular-polysaccharides-specific antibodies, colonization, group B Streptococcus, mucosal immunity, neonatal infection, group B Streptococcus, neonatal infection, colonization, mucosal immunity, capsular-polysaccharides-specific antibodies, GBS vaccine, 1107 Immunology, Immunology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Clin Exp Immunol
ISSN: 1365-2249
Language: eng
Dates:
DateEvent
19 August 2022Published
8 July 2022Published Online
27 June 2022Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MR/R005982/1Human Infection Challenge Network for Vaccine DevelopmentUNSPECIFIED
UNSPECIFIEDGCRF Networks in Vaccines Research and DevelopmentUNSPECIFIED
UNSPECIFIEDMedical Research Councilhttp://dx.doi.org/10.13039/501100000265
UNSPECIFIEDBiotechnology and Biological Sciences Research Councilhttp://dx.doi.org/10.13039/501100000268
UNSPECIFIEDEuropean UnionUNSPECIFIED
MR/S016570/1UK Research and Innovationhttp://dx.doi.org/10.13039/100014013
UNSPECIFIEDErasmus+ Mundus joint Master Degree Leading International Vaccinology EducationUNSPECIFIED
2018-1484Education, Audiovisual and Culture Executive Agencyhttp://dx.doi.org/10.13039/501100000785
UNSPECIFIEDEuropean Commissionhttp://dx.doi.org/10.13039/501100000780
PubMed ID: 35802786
Web of Science ID: WOS:000827388500001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114524
Publisher's version: https://doi.org/10.1093/cei/uxac066

Actions (login required)

Edit Item Edit Item